Cytology is a simple, rapid, and inexpensive method used for pre-operative diagnosis of canine mammary tumors (CMTs) in veterinary practice. Studies related to human breast cancer showed the Robinson’s grading system—established for invasive ductal carcinoma, not otherwise specified (IDC, NOS) and used on cytological material—to not only closely correspond to the histopathological grading but also be helpful in assessing prognosis and selecting most suitable treatments before surgery. The objectives of this study were: to evaluate the accuracy of cytological diagnosis and cytological Robinson’s grading system compared to the histopathological examination of CMTs; to compare of cytological features and cytomorphometric parameters with tumor behavior, as well as cytological and histological grading; and to determine an association of the Robinson’s grading system and cytological background details with metastases, and patients’ survival. We report substantial diagnostic accuracy in detecting simple types and high grade tumors. Cytological diagnosis of tumor behavior showed relatively low sensitivity and specificity compared to human studies, and this might be caused by the heterogeneous morphology of CMTs. The presence of mucosecretory material and extracellular matrix was not significantly associated with tumor behavior. We report a positive correlation between both grading systems and cytological features (included in Robinson’s grading), the presence of necrotic debris, inflammation, and red blood cells. A negative correlation was determined only for the presence of extracellular matrix. The univariate and multivariate analyses confirmed a significantly higher risk of developing metastasis and shorter overall survival for dogs with tumors of grade 2 or 3 on cytology. In addition, these tumors were the most common cause of CMT-related deaths in dogs. Taken together, our findings suggest that the Robinson’s method of cytological grading applied for malignant CMTs evaluated in cytological smears regardless of tumor type can be adapted to veterinary cytology. Additionally, some background features seem to aid malignancy assessment.

Background: The incidence of Crohn’s disease (CD) is increasing worldwide, and it has currently become a serious public health issue in society. The treatment of CD continues throughout a patient’s lifetime, and therefore, it is necessary to develop new, effective treatment methods, including dietotherapy. The present study aimed to determine the effects of consumption of oat beta-glucans with different molar mass on colon inflammation (colitis) in the early stages of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced CD in an animal model. Methods: Sprague–Dawley rats (control and TNBS-induced CD) were divided into three dietary groups and fed for 3 days (reflecting acute inflammation) or 7 days (reflecting remission) with a feed containing 1% low (βGl) or high (βGh) molar mass oat beta-glucan or a feed without this polysaccharide. The level of colon inflammatory markers and the expression of cytokines and their receptor genes were measured by ELISA and RT-PCR methods, respectively. Results: Acute inflammation or remission (3 or 7 days after TNBS administration, respectively) stages of experimentally induced CD were characterized by an increase in the level of inflammatory markers (IL-1, IL-6, IL-10, IL-12, TNF-α, CRP, MPO, COX, and PGE2) and the disruption of some cytokine signaling pathways as well as macro- and microscopic changes of colon tissue. The consumption of oat beta-glucans reduced the level of inflammatory markers and recovered the signaling pathways and histological changes, with stronger effects of βGl after 7 days of colitis. Conclusions: Dietary oat beta-glucans can reduce colitis at the molecular and organ level and accelerate CD remission.

Details var a2a_config = a2a_config || {}; a2a_config.onclick = 1; a2a_config.locale = "pl"; a2a_config.color_main = "D7E5ED"; a2a_config.color_border = "9D9D9D"; a2a_config.color_link_text = "ffffff"; a2a_config.color_link_text_hover = "ffffff"; a2a_config.color_bg = "d9d9d9"; a2a_config.icon_color = "#4e4e4e"; a2a_config.exclude_services = ["dihitt", "delicious", "whatsapp", "dzone", "sms", "stumpedia", "viber", "yahoo_messenger", "google_plus"]; Details PDF BIBTEX RIS Title Epidemiological and morphological analysis of feline injection site sarcomas Journal title Polish Journal of Veterinary Sciences Yearbook 2015 Issue No 2 Authors Kliczkowska, K. ; Czopowicz, M. ; Jankowska, U. ; Jagielski, D. ; Sapierzyński, R. Divisions of PAS Nauki Biologiczne i Rolnicze Publisher Polish Academy of Sciences Committee of Veterinary Sciences ; University of Warmia and Mazury in Olsztyn Date 2015[2015.01.01 AD - 2015.12.31 AD] Identifier DOI: 10.1515/pjvs-2015-0041 ; ISSN 1505-1773 Source Polish Journal of Veterinary Sciences; 2015; No 2 References Shaw (2009), Temporal changes in characteristics of injection - site sarcomas in cats cases, J Am Vet Med Assoc, 392. ; Romanelli (2008), Analysis of prognostic factors associated with injection - site sarcomas in cats cases, J Am Vet Med Assoc, 57. ; Powers (1995), Tumour diagnosis grading and staging, Semin Vet Med Surg Small, 10, 158. ; Hendrick (1992), Postvaccinal sarcomas in the cat : epidemiology and electron probe microanalytical identification of aluminium, Cancer Res, 52, 5391. ; Couto (2002), Feline vaccine - associated fibrosarcoma : morphologic distinctions, Vet Pathol, 39, 33, doi.org/10.1354/vp.39-1-33 ; Hendrick (1991), Do injection site reactions induce fibrosarcoma in cats, J Am Vet Med Assoc, 199. ; Daly (2008), Fibrosarcoma adjacent to the site of microchip implantation in a cat, J Feline Med Surg, 10. ; Day (2010), Vaccination Guidelines Group WSAVA guidelines for the vaccination of dogs and cats, J Small Anim Pract, 51, 1, doi.org/10.1111/j.1748-5827.2010.00959a.x ; Wilcock (2012), Feline postvaccinal sarcoma years later, Can Vet J, 53, 20. ; Giudice (2010), Feline injection - site sarcoma : recurrence , tumour grading and surgical margin status evaluated using the three - dimensional histological technique, Vet J, 186. ; Esplin (1999), Fibrosarcoma at the site of lufenuron injection in a cat, Vet Canc Soc Newslet, 23, 8. ; Dean (2013), The incidence of feline injection site sarcomas in the United Kingdom, BMC Vet Res, 9, 17, doi.org/10.1186/1746-6148-9-17 ; Kirpensteijn (2006), Feline injection site - associated sarcoma : Is it a reason to critically evaluate our vaccination policies, Vet Microbiol, 117. ; Martano (2011), Feline injection - site sarcoma : past , present and future perspectives, Vet J, 188. ; Hendrick (1994), Postvaccinal sarcomas in the cat : histology and immunohistochemistry, Vet Pathol, 31. ; Kuntz (1997), Prognostic factors for surgical treatment of soft - tissue sarcomas in dogs cases, J Am Vet Med Assoc, 75. ; Kass (2003), Multicenter case - control study of risk factors associated with development of vaccine - associated sarcomas in cats, J Am Vet Med Assoc, 223. ; Munday (2011), Development of an injection site sarcoma shortly after meloxicam injection in an unvaccinated cat, J Feline Med Surg, 13. ; Gobar (2002), World Wide Web - based survey of vaccination practices , postvaccinal reactions , and vaccine site - associated sarcomas in cats, J Am Vet Med Assoc, 220. ; McEntee (2001), Feline vaccine - associated sarcomas, J Vet Intern Med, 15. ; Carminato (2011), Microchip - associated fibrosarcoma in a cat, Vet Dermatol, 22, 565, doi.org/10.1111/j.1365-3164.2011.00975.x ; Hendrick (1994), Comparison of fibrosarcomas that developed at vaccination sites and at nonvaccination sites in cats cases, J Am Vet Med Assoc, 239. ; Martano (2012), A case of feline injection - site sarcoma at the site of cisplatin injections, J Feline Med Surg, 14, 751, doi.org/10.1177/1098612X12449407